Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Greater understanding of factors associated with the high placebo-response rates noted in recent neuropathic pain trials may improve trial design. This study investigated placebo response and its predictors in pregabalin trials in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia. PATIENTS AND METHODS: Individual patient data from 16 randomized, placebo-controlled, double-blind trials of pregabalin in 3,053 patients with DPN and 1,460 patients with postherpetic neuralgia were pooled (by condition and all together) in order to investigate the placebo response and its predictors. Univariate and multivariate analyses were performed across all 16 trials to identify predictors of change in pain score in patients. Trials with a >2-point mean reduction in pain score at endpoint with placebo were designated high placebo response and were compared with low placebo-response trials (those with a ≤2-point mean reduction) with respect to patient and study characteristics. RESULTS: Three high placebo-response studies were identified, with all in DPN patients and all conducted postapproval of pregabalin. Younger age, higher mean baseline pain score, longer study duration, higher ratio of patients on active treatment to placebo, and study conducted postapproval were all significantly associated with a higher placebo response (P<0.05). There was a trend towards an increased placebo response in all studies over time without any corresponding change in the response to pregabalin. CONCLUSION: Consideration of the factors identified here as contributing to a higher placebo response could help improve the sensitivity and accuracy of clinical trials in patients with neuropathic pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471 · cited 1×
“” A 2-point mean change was selected because this degree of improvement is generally considered to be clinically meaningful in patients with chronic pain.(24) High placebo-response and low placebo-response trials were pooled and compared with respect to patient and study characteristics.”
ResultA Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought
Price, D. D., Finniss, D. G., & Benedetti, F. (2008) · Annual Review of Psychology · doi:10.1146/annurev.psych.59.113006.095941 · Cited by 1,146
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“75 trials in major depressive disorder noted a significant positive association between the proportion of patients responding to placebo and the year of publication (increase in the proportion of patients responding to placebo of approximately 7% per decade between 1981 and 2000).(33) However, a more recent analysis o…”
Meta-analysis of the placebo response in antidepressant trials.
Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.029 · Cited by 346 · cited 2×
“and positive studies were included.(5,36) Some recent studies have excluded patients with the highest baseline pain scores (to increase the drug–placebo difference).”
The placebo effect in irritable bowel syndrome trials: a meta‐analysis1
Patel, S. M., Stason, W. B., Legedza, A., Ock, S. M., Kaptchuk, T. J., Conboy, L., Canenguez, K., Park, J. K., Kelly, E., Jacobson, E., et al. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00650.x · Cited by 285 · cited 1×
“Pooled analyses in depression, 26 migraine, 27 and irritable bowel syndrome 28 all support an inverse relationship between probability of receiving placebo and placebo response.”
Khan, A., Bhat, A., Kolts, R., Thase, M. E., & Brown, W. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00151.x · Cited by 78
Cepeda, M. S., Berlin, J. A., Gao, C. Y., Wiegand, F., & Wada, D. R. (2012) · Pain Medicine · doi:10.1111/j.1526-4637.2012.01340.x · Cited by 71
Cited by
Pregabalin for neuropathic pain in adults
Derry, S., Bell, R. F., Straube, S., Wiffen, P. J., Aldington, D., & Moore, R. A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007076.pub3 · Cited by 364
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
“[237] evaluated patient-level data from 16 double-blind RCTs of pregabalin in pDPN (N = 3053) and postherpetic neuralgia (N = 1460).”
BackgroundMethodInfluentialHochberg, M. C., Carrino, J. A., Schnitzer, T. J., Guermazi, A., Walsh, D. A., White, A., Nakajo, S., Fountaine, R. J., Hickman, A., Pixton, G., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41674 · Cited by 80
“Over the course of the tanezumab development program, we have observed an increased placebo effect from phase II studies of intravenous treatment to phase III studies of SC treatment, a trend that was similarly observed in the pregabalin development program (34,35).”
Does duration of neuropathic pain impact the effectiveness of pregabalin?
Pérez, C., Latymer, M., Almas, M., Ortiz, M., Clair, A., Parsons, B., & Varvara, R. (2017) · Pain Practice · doi:10.1111/papr.12469 · Cited by 19
Self-citation
Metadata
- Authors
- Fink, J., Freeman, R., Emir, B., & Parsons, B.
- Venue
- Journal of Pain Research
- Publisher
- Informa UK Limited
- Published
- 2015-06
- Volume
- 8
- Pages
- 257
- ISSN
- 1178-7090 (ISSN-L)
- OpenAlex
- W2158719692
- Cited by
- 35
- References
- 7
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials. https://app.cochat.ai/papers/10.2147/jpr.s78303
- The paper
- Fink, J., Freeman, R., Emir, B., & Parsons, B. (2015). Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials. Journal of Pain Research. https://doi.org/10.2147/jpr.s78303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.